Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 31;29(9):2295–2306. doi: 10.1038/s41591-023-02491-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 9 — (a) Positron emission tomography scan image of hepatic extramedullary relapse post anti-GPRC5D TCE. (b) scCNV heatmap comparing the copy number changes in chromosomes 1-22 in pre-therapy (pre) versus post-relapse (post) CD138 + MM cells. Bone marrow CD138+ cells were predominantly enriched with normal polyclonal plasma cells as evidenced by diploid population. (c) Pre-therapy versus post-relapse CD138+ copy number alteration at GPRC5D locus based on scCNV. Barplot and table comparing the percentages of cells harboring the CNV in pre- versus post-TCE relapse samples. (d, e) Immunohistochemistry (IHC) staining of CD138 and GPCR5D expression on (d) control cell lines OPM2 (positive control) and KMS12PE (negative control) and (e) liver biopsy sample from patient. (f) Flow cytometry assay of CD138 and GPRC5D expression on OPM2 (positive control) and liver biopsy sample from patient. Post relapse CD138+ cell are negative for GPRC5D by both IHC and flow cytometry.